Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting Study met primary and secondary endpoints – statistically significant effects on neuroimaging...
Phase 2a Study Published in Antimicrobial Agents and Chemotherapy Shows Potential of Sisunatovir (RV521) to Combat Respiratory Syncytial Virus Infection London, UK, November 18, 2019 – ReViral Ltd., a clinical-stage company focused on developing novel, antiviral...
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis – MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen – –...
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants VANCOUVER, Nov. 7, 2019 /CNW/ – Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and...
Deciphera Pharmaceuticals Presents Updated Data from Ripretinib and DCC-3014 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Median Progression Free Survival (mPFS) of 46 Weeks for the Second-Line...
Recent Comments